METHODS FOR DETERMINING RESPONSIVENESS TO A DIHYDROFOLATE REDUCTASE INHIBITOR
The present disclosure provides methods for predicting or determining the sensitivity of a cell and/or biological sample obtained from a subject to a DHFR inhibitor including, for example, an antifolate such as Methotrexate or Pemetrexed. Such methods may comprise determining the expression level of one or more miRNAs (e.g., one or more members of the miR-181 and/or miR-143 families) in a cell or biological sample. The methods may be used to determine the responsiveness of a subject to treatment with a DHFR inhibitor.
1 . A method for determining sensitivity of a test cell to a dihydrofolate reductase (DHFR) inhibitor, the method comprising:
a. contacting a test cell with a DHFR inhibitor;
b. assaying the test cell for expression of one or more miRNAs;
c. determining if expression of the one or more miRNAs in the test cell is elevated or reduced compared to a control cell or above or below a threshold; and
d. employing the determination of the expression of the one or more miRNAs in the test cell to determine sensitivity of the test cell to the DHFR inhibitor,
wherein the test cell has mutated RAS and no amplification of the RAS gene.
2 . The method of claim 1 , wherein the miRNA is from the miR-181 family and/or the miR143 family.
3 . The method of claim 1 , wherein the DHFR inhibitor is an antifolate.
4 . The method of claim 3 , wherein the antifolate is Methotrexate or Pemetrexed.
5 . The method of claim 4 , wherein RAS is KRAS (SEQ ID NO: 1).
6 . The method of claim 5 , wherein the KRAS mutations are at one or more of positions 12, 13 or 61.
7 . The method of claim 5 , wherein the KRAS mutations are selected from the group consisting of: G12A, G12N, G12R, G12C, G12S, G12V, G13N and Q61H.
8 . The method of claim 1 , wherein the test cell is from a tumor biopsy.
9 . The method of claim 1 , wherein the test cell is from an aspirate, blood, or serum.
10 . The method of claim 1 , wherein the test cell is from a cancer patient.
11 . The method of claim 1 , wherein the test cell is determined to be sensitive to the DHFR inhibitor where expression of the one or more miRNAs in the test cell is elevated as compared to expression of the one or more miRNAs in the control cell or is above the threshold.
12 . The method of claim 1 , wherein the step of assaying the test cell for expression of one or more miRNAs is performed by in situ hybridization (ISH), Northern blot, qRT-PCR or microarray analysis.
13 . The method of claim 1 , wherein the threshold is set at a level of miRNA expression above which the control cell is known to be sensitive to treatment with the DHFR inhibitor and below which the control cell is known to not be sensitive to treatment with the DHFR inhibitor.
14 . The method of claim 11 , wherein the control cell is the same cell type as the test cell.
15 . The method of claim 11 , wherein the control cell is a different cell type than the test cell.
16 . The method of claim 11 , wherein the threshold is set at a level of miRNA expression above which 50%, 60%, 70%, 80%, 90%, or 95% of control cells respond to treatment with the DHFR inhibitor.
17 . The method of claim 11 , wherein the threshold is set at a level of miRNA expression below which 50%, 60%, 70%, 80%, 90%, or 95% of control cells do not respond to treatment with the DHFR inhibitor.
18 . A method for screening one or more dihydrofolate reductase (DHFR) inhibitors for a pharmacological activity, the method comprising:
a. contacting a test cell with the one or more DHFR inhibitors;
b. assaying the contacted test cell for expression of one or more miRNAs;
c. determining if expression of the one or more miRNAs in the test cell is elevated or reduced compared to a control cell or above or below a threshold; and
d. employing the determination of the expression of the one or more miRNAs in the test cell to determine a pharmacological activity of the DHFR inhibitor,
wherein the test cell has mutated RAS and no amplification of the RAS gene.
19 - 35 . (canceled)
36 . A method for determining responsiveness of a subject with a disease or disorder to a dihydrofolate reductase (DHFR) inhibitor, the method comprising:
a. administering a DHFR inhibitor to the subject;
b. obtaining a biological sample from the subject;
c. assaying the biological sample for expression of one or more miRNAs;
d. determining if expression of the one or more miRNAs in the biological sample is elevated or reduced compared to a control sample or above or below a threshold; and
e. employing the determination of the expression of the one or more miRNAs in the biological sample to determine responsiveness of the subject to the DHFR inhibitor,
wherein the biological sample comprises cells with mutated RAS and no amplification of the RAS gene.
37 - 56 . (canceled)